Diabetes Metab J.  2024 Sep;48(5):1012-1013. 10.4093/dmj.2024.0485.

Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)

• Park YH
• Sohn M
• Lim S

• KMID: 2559012
• DOI: http://doi.org/10.4093/dmj.2024.0485

Reference

1. Park YH, Sohn M, Lee SY, Lim S. Two-year therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and empagliflozin in drug-naïve type 2 diabetes mellitus patients. Diabetes Metab J. 2024; 48:253–64.

2. Lim S, Ku EJ, Lee SY, Lee JH, Lee JE, Kim KM, et al. Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study. BMJ Open Diabetes Res Care. 2020; 8:e000807.

3. Abdul-Ghani M, Puckett C, Adams J, Khattab A, Baskoy G, Cersosimo E, et al. Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT. Diabetes Care. 2021; 44:433–9.

4. Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2015; 17:268–75.

5. Kim NH, Moon JS, Lee YH, Cho HC, Kwak SH, Lim S, et al. Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): a multicentre, randomized, 104-week, open-label, active-controlled trial. Diabetes Obes Metab. 2024; 26:3642–52.